Skip to main content
. 2022 May 2;13:872188. doi: 10.3389/fphar.2022.872188

FIGURE 7.

FIGURE 7

Naringenin alleviates LPS-induced bone loss. (A) Representative μCT analysis of trabecular bone of the distal femur. (B–D) Calculations of bone volume/total volume (BV/TV), trabecular bone mineral density (BMD), and trabecular number (Tb.N). (E) Representative H&E staining of distal femoral sections. (F) Quantification of trabecular area (Tb.Ar) from H&E staining. (G) Osteocalcin (OCN) stained sections of the distal femur. Original magnification ×40. (H) Osteoblast (OCN positive) number per bone surface (Ob.N/BS). (I) Serum level of osteoblast marker OCN. (J) Representative calcein staining of trabecula of distal femoral sections. (K) Quantification analysis of calcein staining. Mineral apposition rate (MAR) and bone formation rate per unit of bone surface (BFR/BS). (L) Tartrate-resistant acid phosphatase (TRAP) stained sections of the distal femur. Scale bar: 20 μm. (M) Osteoclast (nuclei>3; TRAP positive) number per bone surface (Ob.N/BS). (N) Serum level of osteoclast marker CTX-I. n = 5 replicates per group in all panels. Data are expressed as mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001.